Page 1 | Search Results | Cancer Prevention Research | American Association for Cancer Research

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Phase II Clinical Chemoprevention Trial of Weekly Erlotinib before Bladder Cancer Surgery

Cancer Prev Res (Phila) (2025) 18 (1): 31–39.

https://doi.org/10.1158/1940-6207.CAPR-24-0194

Published: 06 January 2025

View articletitled, Phase II Clinical Chemoprevention Trial of Weekly Erlotinib before Bladder Cancer Surgery

Journal Articles

A Systematic Review and Pooled Analysis of Hypothesized versus Observed Effect Sizes in Early Phase Cancer Prevention Clinical Trials

Jens Eickhoff, Jen Zaborek, Guanhua Chen, Vikrant V. Sahasrabuddhe, Leslie G. Ford, Eva Szabo, KyungMann Kim

Cancer Prev Res (Phila) (2023) 16 (8): 471–478.

https://doi.org/10.1158/1940-6207.CAPR-23-0060

Published: 01 August 2023

View articletitled, A Systematic Review and Pooled Analysis of Hypothesized versus Observed Effect Sizes in Early Phase Cancer Prevention Clinical Trials

Journal Articles

A Randomized, Placebo-Controlled, Double-Blind, Dose Escalation, Single Dose, and Steady-State Pharmacokinetic Study of 9cUAB30 in Healthy Volunteers

Jill M. Kolesar, Shannon Andrews, Heather Green, Tom C. Havighurst, Barbara W. Wollmer, Katina DeShong, Douglas E. Laux, Helen Krontiras, Donald D. Muccio, KyungMann Kim, Clinton J. Grubbs, Margaret G. House, Howard L. Parnes, Brandy M. Heckman-Stoddard, Howard H. Bailey

Cancer Prev Res (Phila) (2019) 12 (12): 903–912.

https://doi.org/10.1158/1940-6207.CAPR-19-0310

Published: 03 December 2019

View articletitled, A Randomized, Placebo-Controlled, Double-Blind, Dose Escalation, Single Dose, and Steady-State Pharmacokinetic Study of 9cUAB30 in Healthy Volunteers

Journal Articles

A Phase II Randomized, Double-blind, Presurgical Trial of Polyphenon E in Bladder Cancer Patients to Evaluate Pharmacodynamics and Bladder Tissue Biomarkers

Jason R. Gee, Daniel R. Saltzstein, KyungMann Kim, Jill Kolesar, Wei Huang, Thomas C. Havighurst, Barbara W. Wollmer, Jeanne Stublaski, Tracy Downs, Hasan Mukhtar, Margaret G. House, Howard L. Parnes, Howard H. Bailey

Cancer Prev Res (Phila) (2017) 10 (5): 298–307.

https://doi.org/10.1158/1940-6207.CAPR-16-0167

Published: 01 May 2017

View articletitled, A Phase II Randomized, Double-blind, Presurgical Trial of Polyphenon E in Bladder Cancer Patients to Evaluate Pharmacodynamics and Bladder Tissue Biomarkers

Journal Articles

Clinical Trial of Acolbifene in Premenopausal Women at High Risk for Breast Cancer

Carol J. Fabian, Bruce F. Kimler, Carola M. Zalles, Teresa A. Phillips, Trina Metheny, Brian K. Petroff, Thomas C. Havighurst, KyungMann Kim, Howard H. Bailey, Brandy M. Heckman-Stoddard

Cancer Prev Res (Phila) (2015) 8 (12): 1146–1155.

https://doi.org/10.1158/1940-6207.CAPR-15-0109

Published: 03 December 2015

View articletitled, Clinical Trial of Acolbifene in Premenopausal Women at High Risk for Breast Cancer

Includes: Supplementary data

Journal Articles

Abstract A20: A phase II randomized, presurgical placebo-controlled trial of polyphenon E in bladder cancer patients to evaluate bladder tissue levels of EGCG and biomarkers of growth and apoptosis

Jason R. Gee, Daniel R. Saltzstein, KyungMann Kim, Jill Kolesar, Wei Huang, Tom Havighurst, Barbara W. Wollmer, Jeanne Stublaski, Tracy Downs, Hasan Mukhtar, Margaret House, Howard Parnes, Howard Bailey

Cancer Prev Res (Phila) (2015) 8 (10_Supplement): A20.

https://doi.org/10.1158/1940-6215.PREV-14-A20

Published: 02 October 2015

View articletitled, Abstract A20: A phase II randomized, presurgical placebo-controlled trial of polyphenon E in bladder cancer patients to evaluate bladder tissue levels of EGCG and biomarkers of growth and apoptosis

Journal Articles

Abstract A73: Randomized placebo-controlled trial of pioglitazone for oral premalignant lesions: A cross-consortium collaborative study in progress

Jay O. Boyle, Frank G. Ondrey, Powel H. Brown, Howard H. Bailey, KyungMann Kim, Adel K. El-Naggar, Eva M. Szabo

Cancer Prev Res (Phila) (2010) 3 (12_Supplement): A73.

https://doi.org/10.1158/1940-6207.PREV-10-A73

Published: 24 October 2014

View articletitled, Abstract A73: Randomized placebo-controlled trial of pioglitazone for oral premalignant lesions: A cross-consortium collaborative study in progress

Journal Articles

Abstract A52: A phase III skin cancer chemoprevention study of DFMO in subjects with a history of non-melanoma skin cancer (NMSC): Follow-up of NMSC events greater than 5 years post-study participation

Sarah M. Lamont, Kyungmann Kim, Thomas Havighurst, Eneida Mendonça, Gary S. Wood, Stephen Snow, Howard H. Bailey

Cancer Prev Res (Phila) (2011) 4 (10_Supplement): A52.

https://doi.org/10.1158/1940-6207.PREV-11-A52

Published: 23 October 2014

View articletitled, Abstract A52: A phase III skin cancer chemoprevention study of DFMO in subjects with a history of non-melanoma skin cancer (NMSC): Follow-up of NMSC events greater than 5 years post-study participation

Journal Articles

A Phase III Skin Cancer Chemoprevention Study of DFMO: Long-term Follow-up of Skin Cancer Events and Toxicity

Sarah M. Kreul, Tom Havighurst, KyungMann Kim, Eneida A. Mendonça, Gary S. Wood, Stephen Snow, Abbey Borich, Ajit Verma, Howard H. Bailey

Cancer Prev Res (Phila) (2012) 5 (12): 1368–1374.

https://doi.org/10.1158/1940-6207.CAPR-12-0233

Published: 04 December 2012

View articletitled, A Phase III Skin Cancer Chemoprevention Study of DFMO: Long-term Follow-up of Skin Cancer Events and Toxicity

Journal Articles

A Phase 2 Cancer Chemoprevention Biomarker Trial of Isoflavone G-2535 (Genistein) in Presurgical Bladder Cancer Patients

Edward Messing, Jason R. Gee, Daniel R. Saltzstein, KyungMann Kim, Anthony diSant'Agnese, Jill Kolesar, Linda Harris, Adrienne Faerber, Thomas Havighurst, Jay M. Young, Mitchell Efros, Robert H. Getzenberg, Marcia A. Wheeler, Joseph Tangrea, Howard Parnes, Margaret House, J. Erik Busby, Raymond Hohl, Howard Bailey

Cancer Prev Res (Phila) (2012) 5 (4): 621–630.

https://doi.org/10.1158/1940-6207.CAPR-11-0455

Published: 03 April 2012

View articletitled, A Phase 2 Cancer Chemoprevention Biomarker Trial of Isoflavone G-2535 (Genistein) in Presurgical Bladder Cancer Patients

Journal Articles

A Pilot, First-in-Human, Pharmacokinetic Study of 9cUAB30 in Healthy Volunteers

Jill M. Kolesar, Ryan Hoel, Marcia Pomplun, Tom Havighurst, Jeanne Stublaski, Barbara Wollmer, Helen Krontiras, Wayne Brouillette, Donald Muccio, KyungMann Kim, Clinton J. Grubbs, Howard E. Bailey

Cancer Prev Res (Phila) (2010) 3 (12): 1565–1570.

https://doi.org/10.1158/1940-6207.CAPR-10-0149

Published: 12 December 2010

View articletitled, A Pilot, First-in-Human, Pharmacokinetic Study of 9cUAB30 in Healthy Volunteers

Journal Articles

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Skin Cancer Prevention Study of α-Difluoromethylornithine in Subjects with Previous History of Skin Cancer

Howard H. Bailey, KyungMann Kim, Ajit K. Verma, Karen Sielaff, Paul O. Larson, Stephen Snow, Theresa Lenaghan, Jaye L. Viner, Jeff Douglas, Nancy E. Dreckschmidt, Mary Hamielec, Marcy Pomplun, Harry H. Sharata, David Puchalsky, Eric R. Berg, Thomas C. Havighurst, Paul P. Carbone

Cancer Prev Res (Phila) (2010) 3 (1): 35–47.

https://doi.org/10.1158/1940-6207.CAPR-09-0096

Published: 04 January 2010

View articletitled, A Randomized, Double-Blind, Placebo-Controlled Phase 3 Skin Cancer Prevention Study of α-Difluoromethylornithine in Subjects with Previous History of Skin Cancer

Includes: Supplementary data

Journal Articles

Five-Year Efficacy and Safety Analysis of the Adenoma Prevention with Celecoxib Trial

Cancer Prev Res (Phila) (2009) 2 (4): 310–321.

https://doi.org/10.1158/1940-6207.CAPR-08-0206

Published: 06 April 2009

View articletitled, Five-Year Efficacy and Safety Analysis of the Adenoma Prevention with Celecoxib Trial

Includes: Supplementary data

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Phase II Clinical Chemoprevention Trial of Weekly Erlotinib before Bladder Cancer Surgery

A Systematic Review and Pooled Analysis of Hypothesized versus Observed Effect Sizes in Early Phase Cancer Prevention Clinical Trials

A Randomized, Placebo-Controlled, Double-Blind, Dose Escalation, Single Dose, and Steady-State Pharmacokinetic Study of 9cUAB30 in Healthy Volunteers

A Phase II Randomized, Double-blind, Presurgical Trial of Polyphenon E in Bladder Cancer Patients to Evaluate Pharmacodynamics and Bladder Tissue Biomarkers

Clinical Trial of Acolbifene in Premenopausal Women at High Risk for Breast Cancer

Abstract A20: A phase II randomized, presurgical placebo-controlled trial of polyphenon E in bladder cancer patients to evaluate bladder tissue levels of EGCG and biomarkers of growth and apoptosis

Abstract A73: Randomized placebo-controlled trial of pioglitazone for oral premalignant lesions: A cross-consortium collaborative study in progress

Abstract A52: A phase III skin cancer chemoprevention study of DFMO in subjects with a history of non-melanoma skin cancer (NMSC): Follow-up of NMSC events greater than 5 years post-study participation

A Phase III Skin Cancer Chemoprevention Study of DFMO: Long-term Follow-up of Skin Cancer Events and Toxicity

A Phase 2 Cancer Chemoprevention Biomarker Trial of Isoflavone G-2535 (Genistein) in Presurgical Bladder Cancer Patients

A Pilot, First-in-Human, Pharmacokinetic Study of 9cUAB30 in Healthy Volunteers

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Skin Cancer Prevention Study of α-Difluoromethylornithine in Subjects with Previous History of Skin Cancer

Five-Year Efficacy and Safety Analysis of the Adenoma Prevention with Celecoxib Trial

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only